The Federal Trade Commission launched antitrust investigations of two pending healthcare deals, Johnson & Johnson's $25.4 billion acquisition of Guidant Corp. and DaVita's $3.1 billion acquisition of fellow dialysis provider Gambro Healthcare US. J&J and Guidant said the FTC request was anticipated and the companies expected to close the deal in the third quarter. Both companies have positions in the coronary stent market, a factor that analysts predicted would lead to a tough FTC review. Guidant also is a leader in pacemaker and defibrillator technology. DaVita's acquisition of Gambro would produce a new company likely to top Fresenius Medical Care as the nation's largest dialyis provider and also was expected to draw antitrust scrutiny. -- by Modern Healthcare staff
FTC extends reviews of J&J-Guidant, DaVita-Gambro
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.